Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 179

Results For "NCEs"

2676 News Found

Zydus granted Orphan Drug Designation by USFDA for ZYIL1
Drug Approval | March 22, 2023

Zydus granted Orphan Drug Designation by USFDA for ZYIL1

ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates


Briefs: Man Industries, Jeevan Scientific Technology, Unichem and Torrent Pharmaceuticals
Drug Approval | March 18, 2023

Briefs: Man Industries, Jeevan Scientific Technology, Unichem and Torrent Pharmaceuticals

Man Industries (India) Limited has received a new export order of approximately Rs. 1,300 crores.


Jubilant receives additional CAD 23.8 million loan facility for CMO Montreal facility
News | March 17, 2023

Jubilant receives additional CAD 23.8 million loan facility for CMO Montreal facility

This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec


2654 compounds screened for different activities for GPCR profiling: Dr Jitendra Singh
Policy | March 16, 2023

2654 compounds screened for different activities for GPCR profiling: Dr Jitendra Singh

MoES have identified a potent Anti-cancer molecule named GS/IICT5/6


LifeSigns raises Pre-Series A
News | March 15, 2023

LifeSigns raises Pre-Series A

A funding to expand operations and provide better patient care


Pfizer acquires Seagen for US$ 43 billion to battle cancer
News | March 14, 2023

Pfizer acquires Seagen for US$ 43 billion to battle cancer

Proposed combination enhances Pfizer’s position as a leading company in oncology


Briefs: Lupin and Alembic
News | March 14, 2023

Briefs: Lupin and Alembic

Lupin Bioresearch Centre conducts BA/BE, PK/PD, In-vitro BE and biosimilar studies.


Dr. Lal PathLabs selects Kyndryl for cloud services management
Digitisation | March 14, 2023

Dr. Lal PathLabs selects Kyndryl for cloud services management

Kyndryl's multi-cloud management solution leverages AI-based, cloud-hosted models to provide real-time metrics, events, logs, and traces


Shilpa Medicare gets 2 minor observations from USFDA for Unit VII, Analytical Services Division
Drug Approval | March 13, 2023

Shilpa Medicare gets 2 minor observations from USFDA for Unit VII, Analytical Services Division

The company will be submitting the responses to US FDA observations within stipulated timeline